ZODIAC

• Research type

  Research Study

• Full title

  A Study to Assess the Effects of the Endothelin Receptor Antagonist Zibotentan and the SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes and Elevated Albuminuria: a Randomized Double Blind Cross-Over Trial

• IRAS ID

  1004860

• Contact name

  Hiddo Lambers Heerspink

• Contact email

  h.j.lambers.heerspink@umcg.nl

• Sponsor organisation

  University Medical Center Groningen

• Eudract number

  2021-001324-18

• Clinicaltrials.gov Identifier

  NCT05570305

• Research summary

  The aim of this study is to test the hypothesis that the effects on albuminuria of combination treatment with the ERA Zibotentan and SGLT2i Dapagliflozin are complimentary and additive (primary) while the fluid retaining effects of Zibotentan can be mitigated by Dapagliflozin (secondary).

• REC name

  South Central - Berkshire Research Ethics Committee

• REC reference

  22/SC/0260

• Date of REC Opinion

  29 Sep 2022

• REC opinion

  Further Information Favourable Opinion